Article Versions Notes

Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, et al. Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers. 2022; 14(12):2975. https://doi.org/10.3390/cancers14122975

Yasui, Yutaka, Masayuki Kurosaki, Kaoru Tsuchiya, Yuka Hayakawa, Chitomi Hasebe, Masami Abe, Chikara Ogawa, Kouji Joko, Hironori Ochi, Toshifumi Tada, and et al. 2022. "Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study" Cancers 14, no. 12: 2975. https://doi.org/10.3390/cancers14122975

Yasui, Y., Kurosaki, M., Tsuchiya, K., Hayakawa, Y., Hasebe, C., Abe, M., Ogawa, C., Joko, K., Ochi, H., Tada, T., Nakamura, S., Furuta, K., Kimura, H., Tsuji, K., Kojima, Y., Akahane, T., Tamada, T., Uchida, Y., Kondo, M., ... Izumi, N., on behalf of Japanese Red Cross Liver Study Group. (2022). Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 14(12), 2975. https://doi.org/10.3390/cancers14122975